Literature DB >> 11406340

Vincristine-induced allodynia in the rat.

Natsuko Nozaki-Taguchi1, Sandra R Chaplan, Emiliano S Higuera, Reginald C Ajakwe, Tony L Yaksh.   

Abstract

The aims of this study were two-fold: first, to simplify the method for creating a recently described neuropathic pain model in the rat, and second, to evaluate the effects of a number of drugs with analgesic or antihyperalgesic properties, in this model. Continuous intravenous vincristine infusion (1-100 microg kg(-1) day (-1)) for 14 days resulted in a dose dependent tactile allodynia (as measured by von Frey filaments) by 7 days at doses between 30 - 100 microg kg(-1) day (-1), with a hindlimb motor deficit observed at doses greater than 50 microg kg(-1) day (-1). No thermal hyperalgesia was observed. Systemic morphine, lidocaine, mexiletine and pregabalin (given intraperitoneally) produced significant reduction of the allodynia, while tetrodotoxin was without effect. Continuous intravenous infusion of vincristine in rats thus provides a reliable model of chemotherapy induced neuropathy which may be used in defining the mechanism and pharmacology of this clinically relevant condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406340     DOI: 10.1016/S0304-3959(01)00294-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  27 in total

Review 1.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells.

Authors:  Chiang Siau; Wenhua Xiao; Gary J Bennett
Journal:  Exp Neurol       Date:  2006-06-22       Impact factor: 5.330

4.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

5.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 6.  Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

Authors:  Allyson J Ocean; Linda T Vahdat
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 7.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

Review 8.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 9.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Pregabalin suppresses nociceptive behavior and central sensitization in a rat trigeminal neuropathic pain model.

Authors:  Ye Cao; Hua Wang; Chen-Yu Chiang; Jonathan O Dostrovsky; Barry J Sessle
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.